Who Paid My Doc
Darla Liles
Hematology & Oncology Greenville, NC Medical Doctor
NPI 1528051729 CMS profile 295684
600 Moye Blvd, Greenville, NC 27834
General payments
$10,166
Research payments
$1,962
Ownership & investment interest
$0
Research they led as principal investigator
$4,785,651
Through program year 2025, Darla Liles of Greenville, NC is reported in the CMS Open Payments database as having received $10,166 across 28 general payments and $1,962 in research payments paid to them. Separately, studies naming them as principal investigator received $4,785,651 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 74th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $33 | 2 | |
| 2024 | General | $28 | 2 | |
| 2023 | Research | $1,270 | 2 | |
| 2022 | Research | $692 | 2 | |
| 2021 | General | $78 | 1 | |
| 2019 | General | $10,026 | 23 |
Beside peers
- Darla Liles
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Darla Liles were reported at $33. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Darla Liles | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $10,026 | $529 | $121–$2,516 | $163 |
| 2020 | $0 | $339 | $82–$2,213 | $114 |
| 2021 | $78 | $263 | $49–$1,965 | $132 |
| 2022 | $0 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $28 | $692 | $141–$3,008 | $164 |
| 2025 | $33 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 52 drugsPart D claims
2,136
Drug cost
$7,119,357
Branded share of claims
39.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 149 | $2,806,258 | |
| Imbruvica Ibrutinib | Brand | 40 | $607,325 | |
| Pomalyst Pomalidomide | Brand | 28 | $595,495 | |
| Oxbryta Voxelotor | Brand | 60 | $563,162 | |
| Calquence Acalabrutinib Maleate | Brand | 40 | $524,528 | |
| Iclusig Ponatinib Hcl | Brand | 22 | $431,040 | |
| Ojjaara Momelotinib Dihydrochloride | Brand | 15 | $407,157 | |
| Promacta Eltrombopag Olamine | Brand | 22 | $363,999 | |
| Venclexta Venetoclax | Brand | 34 | $232,061 | |
| Sprycel Dasatinib | Brand | 18 | $219,233 |
The 10 drugs with the highest cost, of 52 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 799 Part D prescribers listed as Hematology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$63,202
Medicare patients
333
Services billed
960
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 46% | |
| Ischemic heart disease | 43% | |
| Chronic kidney disease | 43% | |
| Diabetes | 35% | |
| Heart failure | 34% | |
| Cancer | 32% | |
| Depression | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
32 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in North Carolina
Amit Mehta
Hematology & Oncology · Cary, NC
Michael Morse
Hematology & Oncology · Durham, NC
Shelbi Atrash
Hematology & Oncology · Charlotte, NC
Phillip Febbo
Hematology & Oncology · Durham, NC
Angela Alistar
Hematology & Oncology · Winston Salem, NC
Ravi Paluri
Hematology & Oncology · Winston Salem, NC
Related records
Hematology & Oncology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.